Experimental CAR-T therapy aims to tackle Hard-to-Treat lymphoma
NCT ID NCT07506668
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-stage study is testing a new treatment called RN1701 for people with B-cell lymphoma that has come back or not responded to standard treatments. RN1701 is a type of immunotherapy where a patient's own immune cells are not used; instead, it uses donor cells that are specially designed to find and attack cancer cells. The main goals are to see if the treatment is safe and to get an early look at whether it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RN1701 (a type of CAR-T cell therapy that targets two proteins, CD19 and CD20, on cancer cells)
What this could lead to
If successful, this could point toward a new treatment option for patients with B-cell lymphoma that has not responded to other therapies.
What could go wrong
This is a very early, small study (10-19 participants) focused mainly on safety. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome (CRS) and other toxicities.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.